Matinas BioPharma Investor Presentation Deck
Back skin scale score
Redness score
24
0
0
4
3
0
Effect of Oral LNC IL-17A RNAi in a Murine Imiquimod (IMQ) Psoriasis Model
0
* - p < 0.001 (Day 4-7)
2
3
2
4
Day
HIHH
HHH
5
* - p < 0.001 (Day 4-7)
*
*
HHI
IHI
6 7
HH H
HHHHHH
HH
Scaling
8
HHIHH
Back skin scale score
7
Redness
3 4 5 6 7 8
Days on Study
Redness
32
4
3
1
O
2
Naiive
Naiive
IMQ
H
IMQ
Day 7
LNC 1
Day 7
LNC 1
LNC 2
LNC 2
IL-17 Ab
IL-17 Ab
BalbC mice
(n = 50)
Fold change
2.01
1.5-
1.0-
0.5-
0.0
COPYRIGHT MATINAS BIOPHARMA
Naive
2024
5 Groups
Naïve
IMQ only
LNC1
LNC2
IL-17A murine Ab
IMQ
| 10 µg/mouse daily (oral gavage)
1 mg/kg i.p. qod
Change in IL-17A Tissue mRNA at Day 7
(5 per group)
T
T
LNC 1
47%↓
T
LNC 2
IL-17A Ab
[ Changes in serum cytokine levels not expected in this model]
MATINAS
BIOPHARMAView entire presentation